The SIRT3 activator ganoderic acid D regulates airway mucin MUC5AC expression via the NRF2/GPX4 pathway

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Jiancheng Wang , Jiayao Li , Yingying He , Xiaochun Huang , Jianguo Feng , Li Liu , Yulin Liu , Xian Jiang , Jing Jia
{"title":"The SIRT3 activator ganoderic acid D regulates airway mucin MUC5AC expression via the NRF2/GPX4 pathway","authors":"Jiancheng Wang ,&nbsp;Jiayao Li ,&nbsp;Yingying He ,&nbsp;Xiaochun Huang ,&nbsp;Jianguo Feng ,&nbsp;Li Liu ,&nbsp;Yulin Liu ,&nbsp;Xian Jiang ,&nbsp;Jing Jia","doi":"10.1016/j.pupt.2023.102262","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p><span><span>The expression of MUC5AC, a highly prevalent </span>airway mucin, is regulated by stimulatory factors such as </span>oxidative stress<span><span>. Ganoderic acid D (GAD) activates mitochondrial deacetylase SIRT3. SIRT3 regulates mitochondrial function through deacetylation of </span>mitochondrial proteins, thereby playing a significant role in alleviating oxidative stress-related diseases. Therefore, this study aimed to investigate the mechanisms and rationale underlying the regulation of MUC5AC expression by GAD.</span></p></div><div><h3>Methods</h3><p><span>Human airway epithelial cells (NCI–H292) were exposed to pyocyanin (PCN) to establish an </span><em>in vitro</em><span> cell model of airway mucus hypersecretion. The expression of SIRT3, MUC5AC, and NRF2 pathway proteins in cells was assessed. Cellular mitochondrial morphology and oxidative stress markers were analyzed. C57BL/6 mice were induced with </span><span><em>Pseudomonas aeruginosa</em></span> (PA) to establish an <em>in vivo</em><span> mouse model of airway mucus hypersecretion. The expression of SIRT3 and MUC5AC in the airways was examined. In addition, the differential expression of target genes in the airway epithelial tissues of patients with chronic obstructive pulmonary disease (COPD) was analyzed using publicly available databases.</span></p></div><div><h3>Results</h3><p>The results revealed a significant upregulation of MUC5AC expression and a significant downregulation of SIRT3 expression in relation to airway mucus hypersecretion. GAD inhibited the overexpression of MUC5AC in PCN-induced NCI-H292 cells and PA-induced mouse airways by upregulating SIRT3. GAD activated the NRF2/GPX4 pathway and inhibited PCN-induced oxidative stress and mitochondrial morphological changes in NCI-H292 cells. However, ML385 inhibited the regulatory effects of GAD on MUC5AC expression.</p></div><div><h3>Conclusion</h3><p>The SIRT3 activator GAD downregulated MUC5AC expression, potentially through activation of the NRF2/GPX4 pathway. Accordingly, GAD may be a potential treatment approach for airway mucus hypersecretions.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"83 ","pages":"Article 102262"},"PeriodicalIF":3.3000,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553923000743","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

The expression of MUC5AC, a highly prevalent airway mucin, is regulated by stimulatory factors such as oxidative stress. Ganoderic acid D (GAD) activates mitochondrial deacetylase SIRT3. SIRT3 regulates mitochondrial function through deacetylation of mitochondrial proteins, thereby playing a significant role in alleviating oxidative stress-related diseases. Therefore, this study aimed to investigate the mechanisms and rationale underlying the regulation of MUC5AC expression by GAD.

Methods

Human airway epithelial cells (NCI–H292) were exposed to pyocyanin (PCN) to establish an in vitro cell model of airway mucus hypersecretion. The expression of SIRT3, MUC5AC, and NRF2 pathway proteins in cells was assessed. Cellular mitochondrial morphology and oxidative stress markers were analyzed. C57BL/6 mice were induced with Pseudomonas aeruginosa (PA) to establish an in vivo mouse model of airway mucus hypersecretion. The expression of SIRT3 and MUC5AC in the airways was examined. In addition, the differential expression of target genes in the airway epithelial tissues of patients with chronic obstructive pulmonary disease (COPD) was analyzed using publicly available databases.

Results

The results revealed a significant upregulation of MUC5AC expression and a significant downregulation of SIRT3 expression in relation to airway mucus hypersecretion. GAD inhibited the overexpression of MUC5AC in PCN-induced NCI-H292 cells and PA-induced mouse airways by upregulating SIRT3. GAD activated the NRF2/GPX4 pathway and inhibited PCN-induced oxidative stress and mitochondrial morphological changes in NCI-H292 cells. However, ML385 inhibited the regulatory effects of GAD on MUC5AC expression.

Conclusion

The SIRT3 activator GAD downregulated MUC5AC expression, potentially through activation of the NRF2/GPX4 pathway. Accordingly, GAD may be a potential treatment approach for airway mucus hypersecretions.

SIRT3激活剂ganoderic acid D通过NRF2/GPX4途径调节气道粘蛋白MUC5AC的表达。
目的:MUC5AC是一种高度流行的气道粘蛋白,其表达受氧化应激等刺激因子的调节。Ganoderic acid D(GAD)激活线粒体脱乙酰酶SIRT3。SIRT3通过线粒体蛋白的脱乙酰化调节线粒体功能,从而在缓解氧化应激相关疾病中发挥重要作用。因此,本研究旨在探讨GAD调节MUC5AC表达的机制和原理。方法:将人气道上皮细胞(NCI-H292)暴露于脓青蛋白(PCN)中,建立气道粘液高分泌的体外细胞模型。评估细胞中SIRT3、MUC5AC和NRF2通路蛋白的表达。分析细胞线粒体形态和氧化应激标志物。用铜绿假单胞菌(PA)诱导C57BL/6小鼠建立气道粘液高分泌的体内小鼠模型。检测SIRT3和MUC5AC在气道中的表达。此外,使用公开的数据库分析了靶基因在慢性阻塞性肺病(COPD)患者气道上皮组织中的差异表达。结果:结果显示,MUC5AC表达显著上调,SIRT3表达显著下调与气道粘液高分泌有关。GAD通过上调SIRT3抑制PCN诱导的NCI-H292细胞和PA诱导的小鼠气道中MUC5AC的过表达。GAD激活NRF2/GPX4通路,并抑制PCN诱导的NCI-H292细胞的氧化应激和线粒体形态变化。然而,ML385抑制GAD对MUC5AC表达的调节作用。结论:SIRT3激活剂GAD下调MUC5AC的表达,可能通过激活NRF2/GPX4途径。因此,GAD可能是治疗气道粘液分泌过多的一种潜在方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
41
审稿时长
42 days
期刊介绍: Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信